Lonza is a Swiss-based global contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology industries. The company provides development and manufacturing services across biologics and small molecules, including bioconjugates and antibody–drug conjugates (ADCs), as well as cell and gene therapies. Its capabilities span highly potent active pharmaceutical ingredients (HPAPIs), microbial and mammalian platforms, and sterile drug product activities.
Lonza’s offering covers the full lifecycle from early development to commercial supply, including formulation, process and analytical development, drug substance manufacturing (such as monoclonal antibodies, payload–linker components, and other intermediates), conjugation services, and aseptic fill–finish with options like lyophilization. The company operates major sites in Switzerland (including Visp, Stein, and Basel) and a broader global network in Europe, North America, and Asia, supporting clinical and commercial programs for customers ranging from emerging biotechs to large biopharma.
